Elevated islet amyloid pancreatic polypeptide and proinsulin in lean gestational diabetes

Diabetes

Volumn 46, Issue 4, 1997, Pages 607-614

  Kautzky Willer, A ^a   Thomaseth, K ^b   Ludvik, B ^b   Nowotny, P ^b   Rabensteiner, D ^b   Waldhausl W ^b   Pacini, G ^b   Prager, R ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PROTEIN; C PEPTIDE; GLUCOSE; INSULIN; PANCREAS POLYPEPTIDE; PROINSULIN;

ADULT; ARTICLE; CALORIC INTAKE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 0030902580     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.46.4.607     Document Type: Article

References (60)

1. Buchanan TA , Metzger BE: Gestational diabetes mellitus. In Advances in Endocrinology and Metabolism. Vol. 4. Mazzaferri EL, Bar RS, Eds. Chicago, Mosby, 1993, p. 29-46
2. Ramus RM, Kitzmiller JL: Diagnosis and management of gestational diabetes. Diabetes Rev 2:43-52, 1994
3. Metzger BE: Summary and recommendations of the Third International Workshop Conference on Gestational Diabetes Mellitus. Diabetes 40 (Suppl. 2):197-201, 1991
4. Oats JN, Beischer NA, Grant PT: The emergence of diabetes and impaired glucose tolerance in women who had gestational diabetes. In Gestational Diabetes. Weiss PA, Coustan DR, Eds. New York, Springer Verlag, 1988, p. 199-207
5. Yen SSC, Tsai CC, Vela P: Gestational diabetogenesis: quantitative analyses of glucose-insulin interrelationship between normal pregnancy and pregnancy with gestational diabetes. Am J Obstet Gynecol 111:792-800, 1971
6. Buchanan TA, Catalane PM: The pathogenesis of GDM: implications for diabetes after pregnancy. Diabetes Rev 3:584-601, 1995
7. Ward WK, Johnston CLW, Beard JC, Benedetti TJ, Halter JB, Porte D: Insulin resistance and impaired insulin secretion in subjects with histories of gestational diabetes mellitus. Diabetes 34:861-869, 1985
8. Turner RC, Harris E, Qunsted M, Ponsford C: Two abnormalities of glucose induced insulin secretion: dose-response characteristics and insulin sensitivity Acta Endocrinol 42:222-229, 1979
9. Ryan EA, Imes Sh, Liu D, McManus R, Finegood DT, Polonsky KS, Stuns J: Defects in insulin secretion and action in women with a history of gestational diabetes. Diabetes 44:506-512, 1995
10. Kahn S, D'Alessio DA, Schwartz MW, Fujimoto WY, Ensinck JW, Taborsky GJ, Porte D: Evidence of cosecretion of islet amyloid polypeptide and insulin by beta cells. Diabetes 39:634-638, 1990
11. Ludvik B, Lell B, Hartter E, Schnack C, Prager R: Decrease of stimulated amylin secretion in type II diabetes. Diabetes 40:1615-1619, 1991
12. Sanke T, Hanabusa T, Nakano Y, Oki C, Okai K, Nishimura S, Nanjo K: Plasma islet amyloid polypeptide (amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 34:129-132, 1991
13. Johnson Kh, O'Brian TD, Jordan K, Westermark P: Impaired glucose tolerance is associated with increased islet amyloid polypeptide (IAPP) immunoreactivity in pancreatic beta cells. Am J Pathol 135:245-250, 1986
14. Ohsawa H, Kanatsuka A, Yamaguchi T, Makino H, Yoshida S: Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets. Biochem Biophys Res Commun 160:961-967, 1989
15. Molina JM, Cooper GJS, Leighton B, Olefsky JM: Induction of insulin resistance in vivo by amylin and calcitonin gene-related peptide. Diabetes 39:260-265, 1990
16. Leighton B, Garth J, Cooper GJS: Pancreatic amylin and calcitonin gene-related peptide (CGRP) cause resistance to insulin in skeletal muscle in vitro. Nature 335:632-635, 1988
17. Wilding JP, Khandan-Nia N, Bennet WM, Gilbey SG, Beacham J, Ghatei MA, Bloom SR: Lack of acute effect of amylin (islet associated polypeptide) on insulin sensitivity during hyperinsulinaemic euglycemic clamp in humans. Diabetologia 37:166-169, 1994
18. Nyholm B, Moller N, Gravholt CH, Orskov L, Mengel A, Bryan G, Moyses C, Alberti KGMM, Schmitz O: Acute effects of the human amylin analog AC 137 on basal and insulin-stimulated euglycemic and hypoglycemie fuel metabolism in patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 81:1083-1089, 1996
19. Learning R, Johnson A, Hook G, Hanley R, Baron A: Amylin modulates insulin secretion in humans: studies with an amylin antagonist (Abstract). Diabetologia 38 (Suppl.):A437, 1995
20. Kautzky-Willer A, Thomaseth K, Pacini G, Ludvik B, Streli C, Waldhäusl W, Prager R: Role of islet amyloid polypeptide secretion in insulin-resistant humans. Diabetologia 37:188-194, 1994
21. Thomaseth K, Kautzky-Willer A, Ludvik B, Prager R, Pacini G: Integrated mathematical model to assess β-cell activity during the oral glucose tolerance test. Am J Physiol 270:E522-E531, 1996
22. Porte D, Kahn SE: Hyperproinsulinemia and amyloid in NIDDM: clues to etiology of islet β-cell function? Diabetes 38:1333-1336, 1989
23. Leahy JL: Natural history of β-cell dysfunction in NIDDM. Diabetes Care 13:992-1010, 1990
24. De Fronzo RA, Bonadonna RC, Ferrannini E: Pathogenesis of NIDDM: a balanced overview. Diabetes Care 15:318-368, 1992
25. Davis SN, Piatti PM, Monti L, Brown MD, Branch W, Hales CN, Alberti KGMM: Proinsulin and insulin concentrations following intravenenous glucose challenges in normal, obese, and non-insulin-dependent diabetic subjects. Metabolism 42:30-35, 1993
26. Temple RC, Carrington CA, Luzio SD, Owens DR, Schneider AE, Sobey WJ, Hales CN: Insulin deficiency in non-insulin-dependent diabetes. Lancet i:293-295, 1989
27. Rhodes CJ, Alarcon C: What β-cell defect could lead to hyperproinsulinemia in NIDDM? Diabetes 43:511-517, 1994
28. Reaven GM, Chen YDI, Hollenbeck CB, Sheu WHH, Ostrega D, Polonsky KS: Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance. J Clin Endocrinol Metab 76:44-48, 1994
29. Saad MF, Kahn SE, Nelson RG, Pettit DJ, Knowler WC, Schwarte MW, Kowalyk S, Bennett PH, Porte D Jr: Disproportionally elevated proinsulin in Pima Indians with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 70:1247-1253, 1990
30. Mykkänen L, Haffner SM, Kuusisto J, Hales CN, Laasko M: Serum proinsulin levels are disproportionally increased in elderly prediabetic subjects. Diabetologia 38:1176-1182, 1995
31. Yoshioka N, Kuzuya T, Taniguchi M, Iwamoto Y: Serum proinsulin levels at fasting and after oral glucose laod in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 31:355-360, 1988
32. Swinn RA, Wareham NJ, Gregory R: Excessive secretion of insulin precursors characterizes and predicts gestational diabetes. Diabetes 44:911-915, 1995
33. Dornhorst A, Davies M, Anyaoku V, Hampton SM, Elkeles RS, Beard RW, Johnston DG: Abnormalities in fasting circulating proinsulin concentration in mild gestational diabetes. Clin Endocrin 34:211-213, 1991
34. Ludvik B, Clodi M, Kautzky-Willer A, Schuller M, Graf H, Hartter E, Pacini G, Prager R: Increased levels of circulating islet amyloid polypeptide in patients with chronic renal failure have no effect on insulin secretion. J Clin Invest 94:2045-2050, 1994
35. Pacini G, Bergman RN: MINMOD: computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intraveneous glucose tolerance test. Comp Meth Progr Biomed 23:113-122, 1986
36. Thomaseth K: PANSYM: a symbolic equation generator for mathematical modeling, analysis and control of metabolic and pharmacokinetic systems. Comput Methods Programs Biomed 42:99-112, 1994
37. Sowa R, Sanke T, Hirayama J: Islet amyloid polypeptide amide causes peripheral insulin resistance in vivo in dogs. Diabetologia 33:118-120, 1990
38. Fürnsinn C, Leuvenik H, Roden M, Nowotny P, Schneider B, Rohac M, Pieber T, Clodi M, Waldhäusl W: Islet amyloid polypeptide inhibits insulin secretion in conscious rats. Am J Physiol 267:E300-E305, 1994
39. Bretherton-Watt DS, Gilbey SG, Gathei MA, Beacham J, Macrae AD, Bloom SR: Very high concentrations of islet amyloid polypeptide are necessary to alter the insulin response to intravenous glucose in man. J Clin Endocrinol Metab 74:1032-1035, 1992
40. Lee Y, Stein DT, Pieber TR, Weaver DW, Luskey KL: Fetal amylin expression is increased during normal and diabetic gestation. Diabetologia 36 (Suppl.):A42, 1993
41. Bretherton-Watt DS, Ghatei MA, Bloom SR: Altered islet amyloid polypeptide (amylin) gene expression in rat models of diabetes. Diabetologia 32:881-883, 1989
42. O'Brian TD, Westermark P, Johnson KH: Islet amyloid polypeptide and insulin secretion from isolated perfused pancreas of fed, fasted, glucose-treated, and dexamethasone-treated rats. Diabetes 40:1701-1706, 1991
43. Ogawa A, Harris V, McCorkle SK, Unger RH, Luskey KL: Amylin secretion from the rat pancreas and its selective loss after streptozotocin. J Clin Invest 85:973-976, 1990
44. Kautzky-Willer A, Thomaseth K, Clodi M, Ludvik B, Waldhäusl W, Prager R, Pacini G: β-cell activity and hepatic insulin extraction following dexamethasone administration in healthy subjects. Metabolism 45:486-491, 1996
45. Ludvik B, Clodi M, Kautzky-Willer A, Prager R: Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans. Diabetologia 36:84-87, 1993
46. Menon RK, Cohen RM, Sperling MA, Cutfield WS, Mimouni F, Khoury JC: Tranplacental passage of insulin in pregnant women with insulin-dependent diabetes mellitus: its role in fetal macrosomia. N Engl J Med 323:309-315, 1990
47. Larsen CE, Serdula MK, Sullivan KM: Macrosomia: influence of maternal overweight among a low-income population. Am J Obstet Gynecol 162:490-494, 1990
48. Brown K, Menius A, Sandefer E, Edwards J, James M: The effects of amylin on changes in plasma glucose and gastric emptying following an oral glucose load in conscious dogs (Abstract). Diabetes 43 (Suppl. 1):A536, 1994
49. Young A, Gedulin B, Vine W, Percy A, Rink T: Accelerated gastric emptying in insulin-treated spontaneously diabetic BB rats: investigation of a role for amylin. Diabetologia 38:642-648, 1995
50. Kolterman OG, Gottlieb A, Moyses C, Colburn W: Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue. Diabetes Care 18:1179-1182, 1995
51. Shimizu M, Kawazu S, Tomono S, Ohno T, Utsugi T, Kato N, Ishi C, Ito Y, Murata K: Age related alterations in β-cell function: increased proinsulin and proinsulin-to-insulin molar ratio in elderly, but not in obese subjects without glucose intolerance. Diabetes Care 19:8-11, 1996
52. Nijpels G, Popp-Snijders C, Kostense PJ, Bouter LM, Heine RJ: Fasting proinsulin and 2 h postload glucose levels predict the conversion to NIDDM in subjects with impaired glucose tolerance: the Hoorn Study. Diabetologia 39:113-118, 1996
53. Revers RR, Henry R, Schmeiser L, Kolterman O, Cohen R, Bergenstal R, Polonsky K, Jaspan J, Rubenstein A, Frank B, Galloway J, Olefsky JM: The effects of biosynthetic human proinsulin on carbohydrate metabolism. Diabetes 33:762-770, 1984
54. Clark PM, Levy JC, Cox L, Burnett M, Turner RC, Hales CN: Immunoradiometric assay of insulin, intact proinsulin and 32-33 split proinsulin and radioimmunoassay of insulin in diet-treated type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 35:469-474, 1992
55. Yoshioka N, Kuzuya T, Matsuda A, Iwamoto Y: Effects of dietary treatment on serum insulin and proinsulin response in newly diagnosed NIDDM. Diabetes 38:262-266, 1989
56. Glauber HS, Henry RR, Wallace P, Frank B, Galloway JA, Cohen R, JM Olefsky: The effects of biosynthetic human proinsulin on carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N Engl J Med 316:443-449, 1987
57. Gadot M, Ariav Y, Cerasi E, Kaiser N, Gross DJ: Hyperproinsulinemia in the diabetic Psammamys obesus is a result of increased secretory demand on the β-cell. Endocrinology 136:4218-4223, 1995
58. Persson B, Hanson U, Hartling SG, Binder C: Follow-up of women with previous GDM: insulin, C-peptide, and proinsulin responses to oral glucose load. Diabetes 40 (Suppl. 2):136-141, 1991
59. Hanson U, Persson B, Hartling SG, Binder C: Increased molar proinsulin-to-insulin ratio in women with previous gestational diabetes does not predict later impairment of glucose tolerance. Diabetes Care 19:17-20, 1996
60. Byrne MM, Sturis J, O'Meara NM, Polonsky KS: Insulin secretion in insulin-resistant women with a history of gestational diabetes. Metabolism. 44:1067-1073, 1995